Q&A: Jade CEO talks about reverse merger and IgAN drugsnews2024-10-31T18:21:33+00:00October 31st, 2024|Endpoints News|
Gardasil demand in China sinks, and Merck expects the same next quarternews2024-10-31T17:33:18+00:00October 31st, 2024|Endpoints News|
WuXi in ‘early stages’ of CGT business review; Lonza exec becomes AGC Bio CEOnews2024-10-31T16:15:12+00:00October 31st, 2024|Endpoints News|
Takeda says multiyear restructuring is ‘on track’news2024-10-31T15:21:41+00:00October 31st, 2024|Endpoints News|
Argenx reports Vyvgart sales streak, bolstered by launch in rare neuro disordernews2024-10-31T15:18:29+00:00October 31st, 2024|Endpoints News|
Boehringer, Gubra stop work on obesity drug; Galapagos restarts CAR-T studynews2024-10-31T14:25:49+00:00October 31st, 2024|Endpoints News|
How Define Ventures has changed its approach to AI in health technews2024-10-31T13:39:28+00:00October 31st, 2024|Endpoints News|
Startup Evommune raises $115M for I&I pipelinenews2024-10-31T12:00:24+00:00October 31st, 2024|Endpoints News|
AbbVie adds to T cell engager momentum, with EvolveImmune pact starting at $65Mnews2024-10-31T12:00:02+00:00October 31st, 2024|Endpoints News|
Another Paragon offshoot inks reverse merger as Jade takes Aerovate’s placenews2024-10-31T11:27:04+00:00October 31st, 2024|Endpoints News|
